Re: Hepalink IPO Document and what it says about RVX
in response to
by
posted on
Jan 27, 2020 08:03AM
"Page 307 of this document has the patents that have been filed by Hepalink for "RVX208". Can someone please tell us if this is known stuff, or whether there is new patents being filed?
On page 269, there is a blurb on Clinical Development Plan:
Resverlogix has been continuously discussing with the FDA regarding the clinical development
approach based on phase III trial results. Resverlogix will include 11% of participants from
BETonMACE in the study of CKD indication and plans to move to phase III in 2020."
This must relate to the ongoing study as in Clinicaltrials.gov.
https://clinicaltrials.gov/ct2/show/NCT03160430
Koo